AIMP1 and neoplasm: As an extracellular molecule, C-terminal EMAP II (ct-EMAP II) is known to activate endothelial cells, neutrophils and mononuclear phagocytes [5], [6]; consequently, ct-EMAP II has shown the capacity to prime tumor vasculature for a locally destructive process, or to be anti-angiogenic in its own capacity [1], [8], [9], [10].